GSK Rides Cold, Flu And Pain OTCs In Q4 While Allergy Carries Sanofi
This article was originally published in The Pink Sheet
Executive Summary
Firm's "power brands" in respiratory and pain areas achieved high single-digit sales growth in the fourth quarter on an “earlier and more severe” cold season that also drove overall consumer health sales in the period up 4.3% to $2.65bn.